Dr Lal Pathlabs Ltd Analyst Rating
based on 23 analysts
39.13%
Buy
26.09%
Hold
34.78%
Sell
Based on 23 analysts offering long term price targets for Dr Lal Pathlabs Ltd. An average target of ₹3210.13
Source: S&P Global Market Intelligence
Dr Lal Pathlabs Ltd Share analysis
Dr Lal Pathlabs Ltd price forecast by 23 analysts
Upside of5.55%
High
₹3770
Target
₹3210.13
Low
₹2286
Dr Lal Pathlabs Ltd target price ₹3210.13, a slight upside of 5.55% compared to current price of ₹3026.1. According to 23 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Dr Lal Pathlabs Ltd revenue growth forecast
Expected growth rate Q1, FY2026:24.79%
Forecast
Actual
Including amortisation and stock based compensations
Dr Lal Pathlabs Ltd EPS growth forecast
EPS estimate Q1, FY2026:41.68%
Forecast
Actual
Source: S&P Global Market Intelligence
Dr Lal Pathlabs Ltd Performance
Day's Low
Day's High
₹3,011.1₹3,051.952 Week's Low
52 Week's High
₹1,943.7₹3,653.95
| Returns % | |
| 1 Month Return | -7.75 % |
| 3 Month Return | -7.56 % |
| 1 Year Return | + 12.06 % |
| Market Stats | |
| Previous Close | ₹3,041.45 |
| Open | ₹3,021.00 |
| Volume | 65.18K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹25,420.21Cr |
Dr Lal Pathlabs Ltd Key Statistics
| P/E Ratio | 63.09 |
| PEG Ratio | 5.31 |
| Market Cap | ₹25,420.21 Cr |
| P/B Ratio | 9.94 |
| EPS | 43.4 |
| Dividend Yield | 0.8 |
| Sector | Healthcare |
| ROE | 21.42 |
Dr Lal Pathlabs Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹25,420.21 Cr | 18.47% | 0.55 | ₹362 Cr | ₹2,226 Cr | |
| HOLD | ₹26,364.89 Cr | 126.87% | 0.67 | ₹168 Cr | ₹5,040 Cr | |
| HOLD | ₹66,117.05 Cr | 32.89% | 0.56 | ₹1,811 Cr | ₹12,667 Cr | |
| BUY | ₹10,968.52 Cr | 14.47% | 0.64 | ₹119 Cr | ₹547 Cr | |
| BUY | ₹5,102.04 Cr | 14.44% | 0.54 | ₹69 Cr | ₹571 Cr |
Dr Lal Pathlabs Ltd Mutual Fund Holdings
About Dr Lal Pathlabs Ltd
The company's top products include pathology tests, imaging tests, and preventive health check-ups. Its popular brands include Dr Lal PathLabs, Lal PathLabs, and Lal PathLabs Diagnostics. Dr Lal PathLabs Ltd has over 2000 labs across India, with more than 2000 collection centers, and over 20000 trained professionals. The company is also present in Nepal, Sri Lanka, and Bangladesh.
Dr Lal PathLabs Ltd is committed to providing quality healthcare services and products to its customers. It is ISO 9001:2015 certified and has been accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL).
Share Price: ₹3026.10 per share as on 21 Nov, 2024 04:01 PM
Market Capitalisation: ₹25,420.21Cr as of today
Revenue: ₹660.20Cr as on September 2024 (Q3 24)
Net Profit: ₹130.80Cr as on September 2024 (Q3 24)
Listing date: 23 Dec, 2015
Chairperson Name: Arvind Lal
| Organisation | Dr Lal Pathlabs Ltd |
| Headquarters | Gurgaon |
| Industry | Healthcare |
| E-voting on shares | Click here to vote |
Key events for Dr Lal Pathlabs Ltd
Dr Lal PathLabs Reports Growth Amid Profit Booking - 24 Oct, 2024
Dr Lal PathLabs announced an 18.2% increase in Q2 profit and a 9.8% rise in revenue. Despite strong results, shares fell 6% due to profit booking. Analysts maintain mixed views, with UBS recommending a buy and ICICI lowering its target price.
Dr Lal PathLabs Reports Strong Q2 Results and Dividend - 23 Oct, 2024
Dr Lal PathLabs announced solid Q2 FY25 results with an 18.1% increase in net profit and 9.8% revenue growth. The company also declared a ₹6 interim dividend. Overall, the results exceeded analyst expectations, showcasing strong performance in the diagnostics sector.
Nomura Maintains Buy Rating on Dr Lal PathLabs - 22 Oct, 2024
Nomura has reiterated its 'Buy' rating on Dr Lal PathLabs with a target price of ₹3,720, anticipating steady performance despite modest seasonal demand in FY25. The brokerage notes challenges due to a high comparison base from the previous year, particularly influenced by flu and dengue seasons.
Dr Lal PathLabs Reports Strong Q1 Growth and Innovations - 19 Oct, 2024
Dr Lal PathLabs achieved Rs 6 billion in revenue for Q1 FY25, an 11.3% increase year-over-year, driven by higher patient volumes. The company is expanding its presence in South India and leveraging AI and data analytics to enhance patient experience.
Dr. Lal PathLabs Announces Q2 FY 25 Results Schedule - 16 Oct, 2024
Dr. Lal PathLabs will release its Q2 FY 2024-25 results on October 23, 2024, potentially declaring an interim dividend. The stock has shown significant gains over the past year.
Dr Lal Pathlabs Stock Shows Bullish Momentum - 07 Oct, 2024
Dr Lal Pathlabs stock is exhibiting a bullish breakout, consistently forming higher highs and lows. Despite market downturns, it broke previous highs with strong volume, indicating continued momentum. A buy recommendation is given around Rs 3,495 - Rs 3,480, with a target of Rs 3,816.
Dr Lal PathLabs Plans Major Acquisition in South India - 01 Oct, 2024
Dr Lal PathLabs aims to expand in South India through a potential acquisition worth Rs 3,000-4,000 crore. The company has Rs 1,000 crore in net cash and is forming an M&A team to explore opportunities, targeting assets with Rs 300-400 crore revenue.
Dr Lal PathLabs Plans Expansion and Acquisitions - 30 Sep, 2024
Dr Lal PathLabs aims to double its volume growth by acquiring small and mid-sized diagnostic companies in southern India by FY25. The firm plans to open 20 new labs and targets 6-7% growth in patient volumes, focusing on organic growth and acquisitions after a four-year pause.
Insights on Dr Lal Pathlabs Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 9.30% to 9.84% in Sep 2024 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 81.3 Cr → 129.2 Cr (in ₹), with an average increase of 14.0% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, LALPATHLAB stock has moved up by 2.9%
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 25.42% to 26.82% in Sep 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 557.2 Cr → 682.1 Cr (in ₹), with an average increase of 6.5% per quarter
NO EFFECTAgainst Peers
In the last 1 year, Fortis Healthcare Ltd has given 76.6% return, outperforming this stock by 64.6%
- NO EFFECT
Against Peers
In the last 3 years, Max Healthcare Institute Ltd has given 191.3% return, outperforming this stock by 203.7%
NEGATIVE IMPACTRetail Holding Down
Retail Investor have decreased holdings from 6.96% to 6.04% in Sep 2024 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 54.60% to 53.92% in Sep 2024 quarter
Dr Lal Pathlabs Ltd Financials
Index Inclusions
Dr Lal Pathlabs Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 53.92% | ||
| Foreign Institutions | 26.82% | 5.51 | |
| Mutual Funds | 9.84% | 5.83 | |
| Retail Investors | 6.04% | ||
| Others | 3.38% |
Dr Lal Pathlabs Ltd Key Indicators
Dr Lal Pathlabs Ltd Valuation
Dr Lal Pathlabs Ltd in the last 5 years
Lowest (37.51x)
November 16, 2018
Today (63.09x)
November 19, 2024
Industry (96.41x)
November 19, 2024
Highest (95.62x)
November 5, 2020
Dr Lal Pathlabs Ltd Earnings and Dividends
Dr Lal Pathlabs Ltd Earnings Results
Dr Lal Pathlabs Ltd’s net profit jumped 18.21% since last year same period to ₹129.20Cr in the Q2 2024-2025. On a quarterly growth basis, Dr Lal Pathlabs Ltd has generated 21.43% jump in its net profits since last 3-months.
Read More about Earnings ResultsDr Lal Pathlabs Ltd Dividends October,2024
In the quarter ending September 2024, Dr Lal Pathlabs Ltd has declared dividend of ₹6 - translating a dividend yield of 0.99%.
Read More about Dividends
Dr Lal Pathlabs Ltd Technicals Summary
Bearish
Neutral
Bullish
Dr Lal Pathlabs Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Dr Lal Pathlabs Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Dr Lal Pathlabs Ltd shares.
Dr Lal Pathlabs Ltd (LALPATHLAB) share price today is ₹3026.1
Dr Lal Pathlabs Ltd is listed on NSE
Dr Lal Pathlabs Ltd is listed on BSE
- Today’s highest price of Dr Lal Pathlabs Ltd is ₹3051.9.
- Today’s lowest price of Dr Lal Pathlabs Ltd is ₹3011.1.
PE Ratio of Dr Lal Pathlabs Ltd is 63.09
PE ratio = Dr Lal Pathlabs Ltd Market price per share / Dr Lal Pathlabs Ltd Earnings per share
Today’s traded volume of Dr Lal Pathlabs Ltd(LALPATHLAB) is 65.18K.
Today’s market capitalisation of Dr Lal Pathlabs Ltd(LALPATHLAB) is ₹25420.21Cr.
| Dr Lal Pathlabs Ltd(LALPATHLAB | Price |
|---|---|
52 Week High | ₹3653.95 |
52 Week Low | ₹1943.7 |
Dr Lal Pathlabs Ltd(LALPATHLAB) share price is ₹3026.1. It is down -17.18% from its 52 Week High price of ₹3653.95
Dr Lal Pathlabs Ltd(LALPATHLAB) share price is ₹3026.1. It is up 55.69% from its 52 Week Low price of ₹1943.7
| Dr Lal Pathlabs Ltd(LALPATHLAB | Returns |
|---|---|
1 Day Returns | -15.35% |
1 Month Returns | -7.75% |
3 Month Returns | -7.56% |
1 Year Returns | 12.06% |